CorMedix Inc (NASDAQ:CRMD - Get Free Report) CEO Joseph Todisco purchased 80,000 shares of the firm's stock in a transaction on Friday, November 13th. The shares were purchased at an average cost of $4.89 per share, for a total transaction of $391,200.00. Following the completion of the purchase, the chief executive officer directly owned 854,749 shares in the company, valued at $4,179,722.61. The trade was a 10.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
CorMedix Stock Performance
Shares of NASDAQ CRMD opened at $4.66 on Monday. The company has a 50-day simple moving average of $7.18 and a 200-day simple moving average of $7.57. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.56 and a quick ratio of 2.36. The company has a market cap of $363.22 million, a PE ratio of 6.75, a price-to-earnings-growth ratio of 0.90 and a beta of 1.48. CorMedix Inc has a 12 month low of $4.65 and a 12 month high of $13.02.
CorMedix (NASDAQ:CRMD - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 27.12%. The firm had revenue of $54.52 million for the quarter, compared to analysts' expectations of $51.76 million. On average, equities analysts anticipate that CorMedix Inc will post 0.52 earnings per share for the current year.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Citigroup reiterated a "market outperform" rating on shares of CorMedix in a report on Tuesday, November 10th. Wall Street Zen cut CorMedix from a "hold" rating to a "sell" rating in a report on Saturday. UBS Group set a $19.00 price objective on CorMedix in a report on Tuesday, November 10th. Needham & Company LLC lifted their price objective on CorMedix from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Tuesday, November 10th. Finally, Royal Bank Of Canada upped their target price on CorMedix from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Tuesday, November 10th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.22.
Get Our Latest Analysis on CRMD
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in CorMedix in the second quarter valued at approximately $49,644,000. Marshall Wace LLP increased its position in CorMedix by 53.4% during the third quarter. Marshall Wace LLP now owns 1,195,422 shares of the company's stock worth $9,205,000 after purchasing an additional 415,887 shares during the last quarter. Pacer Advisors Inc. increased its position in CorMedix by 128.7% during the first quarter. Pacer Advisors Inc. now owns 580,620 shares of the company's stock worth $3,942,000 after purchasing an additional 326,724 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in CorMedix by 150.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 438,629 shares of the company's stock worth $3,443,000 after purchasing an additional 263,618 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in CorMedix during the second quarter worth approximately $3,108,000. 34.18% of the stock is currently owned by hedge funds and other institutional investors.
CorMedix Company Profile
(
Get Free Report)
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CorMedix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.
While CorMedix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.